| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -147,7 k € | -49.7% | -98,7 k € | -67.0% | -59,1 k € | -33.3% | -44,3 k € | -41.0% | -31,4 k € | +57.8% | -74,5 k € | -104.3% | -36,5 k € | |
| EBITDA | -149,5 k € | -48.6% | -100,6 k € | -66.1% | -60,5 k € | -32.4% | -45,7 k € | -38.8% | -32,9 k € | +57.7% | -77,9 k € | -94.7% | -40,0 k € | |
| Operating profit | -153,4 k € | -45.6% | -105,4 k € | -42.7% | -73,9 k € | -16.0% | -63,7 k € | -28.4% | -49,6 k € | +47.3% | -94,1 k € | -56.5% | -60,1 k € | |
| Profit/loss | -153,6 k € | -44.7% | -106,2 k € | -42.0% | -74,8 k € | -17.0% | -63,9 k € | -28.3% | -49,8 k € | +47.3% | -94,6 k € | -57.5% | -60,0 k € | |
| Equity | -538,9 k € | -39.9% | -385,3 k € | -38.0% | -279,2 k € | -36.6% | -204,4 k € | -45.5% | -140,5 k € | -55.0% | -90,6 k € | -2393.0% | 4,0 k € | |
| Total assets | 9,3 M € | +14.7% | 8,1 M € | +29.1% | 6,3 M € | +86.9% | 3,4 M € | +18.0% | 2,9 M € | +91.3% | 1,5 M € | +48.7% | 1,0 M € | |
| Cash | 545,9 k € | +93.0% | 282,8 k € | +2.3% | 276,3 k € | +31.8% | 209,7 k € | -2.3% | 214,6 k € | -19.6% | 267,0 k € | -64.4% | 749,5 k € | |
| Debts | 9,9 M € | +15.8% | 8,5 M € | +29.4% | 6,6 M € | +84.1% | 3,6 M € | +19.3% | 3,0 M € | +89.2% | 1,6 M € | +58.4% | 1,0 M € | |
Public limited company · Tubize · incorporated on 07/09/2017
Public limited company loss-making in the latest fiscal year. Cash position rising (+93.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
SHANT BIOTECH is a Public limited company incorporated in 2017. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Tubize.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette